Navigation Links
Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
Date:10/15/2007

-Company to Host Conference Call at 9:00 a.m. EDT-

MONTVALE, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal L-type calcium channel modulator, in Alzheimer's disease. The trial enrolled 183 subjects with mild to moderate Alzheimer's disease at over 40 centers in the United States and included monotherapy subjects and subjects on stable doses of cholinesterase inhibitors. The trial failed to meet its primary endpoint, which was a twelve-week mean change in the Alzheimer's disease Assessment Scale -- Cognitive subscale (ADAS-cog) score in the overall population.

The negative results were largely driven by an unusually large placebo response in the subgroup of monotherapy subjects. In the subgroup of subjects receiving cholinesterase inhibitors, the change in ADAS-cog favored treatment over placebo, although this difference was not statistically significant. Similarly, in this subgroup, numeric improvements were seen in all of the four secondary endpoints, which included the Mini-Mental State Exam, the Alzheimer's Disease Cooperative Study -- Activities of Daily Living, the Clinician Interview-Based Impression of Change with Caregiver Input and the Neuropsychiatric Inventory.

"Based on this information, I believe that further development of this compound merits consideration," said Pierre N. Tariot, M.D., Professor of Research Psychiatry, Director of the Memory Disorders Center of the Banner Alzheimer's Institute in Phoenix, and chairman of the study's data and safety monitoring board.

"While we are disappointed that
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Suggests no Significant Impairment in Middle-of-the-Night Balance, Mobility or Memory in Older Adults Using Ramelteon
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015   InspireMD, Inc. (NYSE MKT: ... protection systems ("EPS"), today announced that its CGuard TM ... principle investigator Prof. Piotr Musialek , at the ... Paris, France . PARADIGM, an investigator-initiated ... c A roti D revascularization I n symptomatic ...
(Date:5/22/2015)... R.I. , May 22, 2015 ... once-daily central nervous system stimulant indicated for the ... to patients beginning Summer 2015. ... XR received approval from the U.S. Food and ... is an extended-release formulation of methylphenidate capsule with ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... Data Presented on Valopicitabine Combined,with an Investigational ... /PRNewswire-FirstCall/ --,Idenix Pharmaceuticals, Inc. today announced results ... combination of valopicitabine (NM283) and,pegylated interferon alfa-2a ... infected with the genotype-1,strain of the hepatitis ...
... 11, 2007 /PRNewswire-FirstCall/ --,Advanced Magnetics today announced ... trials of ferumoxytol as an,intravenous (IV) iron ... approximately 6:00 pm EDT as posters at ... Orlando,Florida. These posters are available in the ...
Cached Medicine Technology:Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 2Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 3Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 4Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 5Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 6Idenix Reports Results from Two Phase IIb Studies of the,Combination of Valopicitabine and Pegylated Interferon in Hepatitis,C Genotype-1 Patients at the 42nd Annual Meeting of the European,Association for the Study of the Liver 7Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 2Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 3Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 4Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 5Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 6Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 7Advanced Magnetics Announces Positive Results from Two Additional,Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement,Therapeutic 8
(Date:5/24/2015)... May 24, 2015 Women’s Excellence ... take pressure measurements in patients’ bladder and urethra. This ... orders it if they have reported symptoms of stress ... , Women’s Excellence in Bladder Control is a comprehensive ... leakage or problems with overall control of their bladder. ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 The ... ( http://www.testosteronelawsuithub.com/ ) has scheduled its next monthly ... the multidistrict litigation. According to court documents filed ... Illinois, the Conference will be convened on June ... Replacement Therapy Product Liability Litigation - MDL No. ...
(Date:5/24/2015)... 24, 2015 Medicx Media Solutions ... strategy executive Jay Krihak as its head of ... ramp up its expertise and leadership position in ... and Health sectors. , Krihak is an experienced, ... recently, Krihak led sales planning teams for mobile ...
(Date:5/23/2015)... FL (PRWEB) May 23, 2015 On Saturday, ... build a new playground for Branches Florida City exactly five ... former play space in 2010. , A large fire tore ... playground on May 23, 2010 in the middle of the ... The fire was later declared arson even though it is ...
(Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3
... Calif., Nov. 30 Thoratec,Corporation (Nasdaq: THOR ... disease, said today that the FDA Circulatory System ... approve, with,conditions, the company,s PMA (PreMarket Approval) allowing ... Assist System) as a,bridge-to-transplantation (BTT)., The HeartMate ...
... with Deployed Service Members ... -, ... Operation Cares, which supports the needs of the,more than 4,000 of South Dakota,s ... central market area at,TriWest, will present the check to Steve Doohen, secretary of ...
... 30 California,s,stem cell agency is inviting for-profit ... time, the Foundation for Taxpayer and Consumer Rights,(FTCR) ... vowed to scrutinize the awards process to prevent ... (CIRM) has just,issued calls for applications for two ...
... The following is a,statement from Henrietta H. ... international community again recognizes World AIDS,Day and the ... living with,HIV/AIDS. Through the President,s Emergency Plan for ... (USAID) is supporting those,battling the disease, as well ...
... Va., Nov. 30 The Pharmaceutical,Care Management ... claiming,that pending legislation requiring prompt payment of ... billions of dollars. PCMA represents 10,pharmacy benefit ... drug plans. In response, Bruce Roberts, RPh, ...
... LAVAL, QC, Nov. 30 /PRNewswire-FirstCall/ - Neurochem Inc. ... Philippe Calais, PhD.,Pharm., Neurochem,s President, Global Business. Dr. ... December 31, 2007, to pursue other,interests., "Dr. ... relationships for Neurochem in international markets and we,are ...
Cached Medicine News:Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 2Health News:Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation 3Health News:TriWest Contributes $10,000 to Operation Cares for South Dakota's Military Families 2Health News:Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say 2Health News:On World AIDS Day, Keeping the Promise to Stop AIDS Through the Power of Partnerships 2Health News:NCPA Statement on Bogus PCMA Study About Cost to Fix Medicare Part D 2Health News:Neurochem announces departure of Dr. Philippe Calais, President, Global Business 2
... The new DeVilbiss PulmoAide Compact Compressor provides effective ... size allows for therapy at home or on ... 5-year warranty, and the same reliable operation you ... ,The PulmoAide Compact Compressor is the perfect solution ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
Medicine Products: